Jason Gerberry
Stock Analyst at B of A Securities
(4.22)
# 378
Out of 5,179 analysts
164
Total ratings
61.48%
Success rate
10.15%
Average return
Main Sectors:
Stocks Rated by Jason Gerberry
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LENZ LENZ Therapeutics | Maintains: Buy | $35 → $29 | $8.40 | +245.24% | 1 | Mar 25, 2026 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $263 → $275 | $182.69 | +50.53% | 7 | Feb 25, 2026 | |
| HRMY Harmony Biosciences Holdings | Maintains: Underperform | $32 → $28 | $26.54 | +5.50% | 3 | Feb 25, 2026 | |
| ALKS Alkermes | Maintains: Neutral | $33 → $34 | $29.39 | +15.69% | 10 | Feb 20, 2026 | |
| PFE Pfizer | Maintains: Neutral | $29 → $28 | $27.04 | +3.55% | 5 | Dec 15, 2025 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Buy | $62 → $81 | $57.78 | +40.19% | 4 | Dec 9, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Buy | $86 → $97 | $72.15 | +34.44% | 7 | Dec 9, 2025 | |
| TEVA Teva Pharmaceutical Industries | Maintains: Buy | $29 → $32 | $28.74 | +11.34% | 15 | Dec 9, 2025 | |
| OCS Oculis Holding AG | Maintains: Buy | $30 → $29 | $24.69 | +17.46% | 4 | Nov 13, 2025 | |
| AMPH Amphastar Pharmaceuticals | Maintains: Neutral | $28 → $32 | $19.01 | +68.33% | 2 | Aug 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $33 → $30 | $23.98 | +25.10% | 6 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $50 → $49 | $8.37 | +485.42% | 2 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $173 → $176 | $156.35 | +12.57% | 6 | Aug 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $3 → $1 | $1.60 | -37.50% | 4 | Jun 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $23 | $35.03 | -34.34% | 2 | Jun 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $45 → $46 | $41.53 | +10.76% | 3 | Jun 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $157 → $137 | $53.16 | +157.71% | 9 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $11 → $10 | $13.05 | -23.37% | 3 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $23.40 | +28.21% | 2 | Jan 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $84 → $100 | $114.57 | -12.72% | 5 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $24 | $9.60 | +150.00% | 1 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $41 → $31 | $28.93 | +7.16% | 6 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $52 → $56 | $54.48 | +2.79% | 2 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $450 → $500 | $878.24 | -43.07% | 15 | May 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $9 | $2.26 | +298.23% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $37 → $25 | $5.84 | +328.08% | 3 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $45 → $5 | $1.60 | +212.50% | 2 | Dec 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $27 | $5.02 | +437.85% | 4 | Mar 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $20 | $1.63 | +1,126.99% | 1 | Jul 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $170 → $100 | $4.38 | +2,183.11% | 1 | Jul 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $95 | $209.40 | -54.63% | 10 | May 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $60 | $58.54 | +2.49% | 7 | Oct 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $90 | $119.63 | -24.77% | 11 | Oct 17, 2019 |
LENZ Therapeutics
Mar 25, 2026
Maintains: Buy
Price Target: $35 → $29
Current: $8.40
Upside: +245.24%
Jazz Pharmaceuticals
Feb 25, 2026
Maintains: Buy
Price Target: $263 → $275
Current: $182.69
Upside: +50.53%
Harmony Biosciences Holdings
Feb 25, 2026
Maintains: Underperform
Price Target: $32 → $28
Current: $26.54
Upside: +5.50%
Alkermes
Feb 20, 2026
Maintains: Neutral
Price Target: $33 → $34
Current: $29.39
Upside: +15.69%
Pfizer
Dec 15, 2025
Maintains: Neutral
Price Target: $29 → $28
Current: $27.04
Upside: +3.55%
Arrowhead Pharmaceuticals
Dec 9, 2025
Maintains: Buy
Price Target: $62 → $81
Current: $57.78
Upside: +40.19%
Ionis Pharmaceuticals
Dec 9, 2025
Maintains: Buy
Price Target: $86 → $97
Current: $72.15
Upside: +34.44%
Teva Pharmaceutical Industries
Dec 9, 2025
Maintains: Buy
Price Target: $29 → $32
Current: $28.74
Upside: +11.34%
Oculis Holding AG
Nov 13, 2025
Maintains: Buy
Price Target: $30 → $29
Current: $24.69
Upside: +17.46%
Amphastar Pharmaceuticals
Aug 26, 2025
Maintains: Neutral
Price Target: $28 → $32
Current: $19.01
Upside: +68.33%
Aug 12, 2025
Maintains: Buy
Price Target: $33 → $30
Current: $23.98
Upside: +25.10%
Aug 12, 2025
Maintains: Buy
Price Target: $50 → $49
Current: $8.37
Upside: +485.42%
Aug 5, 2025
Maintains: Buy
Price Target: $173 → $176
Current: $156.35
Upside: +12.57%
Jun 30, 2025
Downgrades: Underperform
Price Target: $3 → $1
Current: $1.60
Upside: -37.50%
Jun 11, 2025
Maintains: Buy
Price Target: $25 → $23
Current: $35.03
Upside: -34.34%
Jun 5, 2025
Maintains: Neutral
Price Target: $45 → $46
Current: $41.53
Upside: +10.76%
Apr 1, 2025
Maintains: Buy
Price Target: $157 → $137
Current: $53.16
Upside: +157.71%
Feb 28, 2025
Maintains: Underperform
Price Target: $11 → $10
Current: $13.05
Upside: -23.37%
Jan 9, 2025
Reiterates: Buy
Price Target: $30
Current: $23.40
Upside: +28.21%
Nov 6, 2024
Maintains: Buy
Price Target: $84 → $100
Current: $114.57
Upside: -12.72%
Sep 10, 2024
Maintains: Buy
Price Target: $20 → $24
Current: $9.60
Upside: +150.00%
Apr 1, 2024
Downgrades: Underperform
Price Target: $41 → $31
Current: $28.93
Upside: +7.16%
Jan 2, 2024
Maintains: Buy
Price Target: $52 → $56
Current: $54.48
Upside: +2.79%
May 24, 2023
Maintains: Buy
Price Target: $450 → $500
Current: $878.24
Upside: -43.07%
Dec 12, 2022
Downgrades: Underperform
Price Target: $9
Current: $2.26
Upside: +298.23%
Oct 14, 2022
Downgrades: Underperform
Price Target: $37 → $25
Current: $5.84
Upside: +328.08%
Dec 2, 2021
Downgrades: Underperform
Price Target: $45 → $5
Current: $1.60
Upside: +212.50%
Mar 24, 2021
Downgrades: Underperform
Price Target: $27
Current: $5.02
Upside: +437.85%
Jul 16, 2020
Initiates: Neutral
Price Target: $20
Current: $1.63
Upside: +1,126.99%
Jul 15, 2020
Downgrades: Neutral
Price Target: $170 → $100
Current: $4.38
Upside: +2,183.11%
May 18, 2020
Reinstates: Neutral
Price Target: $95
Current: $209.40
Upside: -54.63%
Oct 17, 2019
Reinstates: Buy
Price Target: $60
Current: $58.54
Upside: +2.49%
Oct 17, 2019
Reinstates: Neutral
Price Target: $90
Current: $119.63
Upside: -24.77%